Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
How Do Weight-Loss Outcomes Differ Between The Two
Importantly, this medication is not recommended for individuals with a history of thyroid cancer or Multiple Endocrine Neoplasia
It is the same linear peptide, specifically developed and studied for its high selectivity for the MC1 receptor and its photoprotective effects
$184.99 Shipping Calculated at checkout
In the early stage, GLP-1 drugs had a short half-life in vivo, requiring frequent injections with poor patient compliance
The patient must: Be age 18 or older Have eligible Medicare Part D coverage Be prescribed treatment specifically for weight reduction and maintenance Participate in ongoing nutrition and physical activity intervention Not have already received a GLP-1 through their Part D plan Not be seeking coverage for another Part D-coverable indication, such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, MASH, or cardiovascular risk reduction The patient must also have met one of these criteria when GLP-1 therapy was originally started: BMI 35 BMI 30 plus HFpEF, uncontrolled hypertension despite 2 medications, or CKD stage 3a+ BMI 27 plus prediabetes, prior MI, prior stroke, or symptomatic peripheral artery disease Important: Eligibility is based on BMI at treatment initiation, not necessarily the patients current BMI
US$ 24.18
US$ 20.94
US$ 23.02
US$ 27.22
US$ 27.16
:format(webp))
US$ 22.62
